A recent screening-based study has identified several promising SARM1 inhibitors, including non-competitive inhibitors such as berberine chloride and zinc chloride 233 , suggesting the presence of an allosteric binding pocket that can be targeted for therapeutic development
5 These results are similar to the injectable Wegovy 2.4 mg pen in terms of average weight loss, while delivering the medication as a tablet
April 30, 2024
I see people arguing that because we have not seen a clear increase in aspiration events, there is no need to treat these patients differently
Reducing visceral adiposity has been shown to improve insulin sensitivity, lipid profiles, and inflammatory markers, making it a critical therapeutic target in metabolic disease management
Its also fast-acting, typically beginning to work within 30 to 60 minutes, which allows for a level of spontaneity that other treatments might not